Chinese Clinical Trial Registry: mission, responsibility and operation.

J Evid Based Med

Chinese Clinical Registry, Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, INCLEN CERTC, West China Hospital, Sichuan University, Chengdu 610041, China.

Published: November 2013

As a national public clinical trial registry and a recognized Primary Registry of the WHO ICTRP, the Chinese Clinical Trial Registry (ChiCTR) has responsibility to disseminate knowledge about clinical trial transparency, which is an important ethical issue for healthcare studies involving humans, and to promote the quality of healthcare studies in China. This article describes the mission, policy and operation of the ChiCTR. We discuss the need to improve the quality of clinical trials and our ideas for new developments. The registration of clinical trials is an ethical responsibility and obligation for researchers. A clinical study is a public event itself, which needs the participation of the public, and its results should also be seen as a service to the public. Therefore, the public have the right to know how a study is progressing.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1756-5391.2011.01137.xDOI Listing

Publication Analysis

Top Keywords

clinical trial
16
trial registry
12
chinese clinical
8
healthcare studies
8
clinical trials
8
clinical
6
public
5
trial
4
registry
4
registry mission
4

Similar Publications

Purpose: This study aims to evaluate the effect of acupoint application on the prevention of postoperative sore throat (POST), cough, expectoration, hoarseness, and patient satisfaction after general anesthesia.

Design: Randomized controlled trial.

Methods: A randomized double-blind clinical trial was designed.

View Article and Find Full Text PDF

Background: Malnutrition is common with esophagogastric cancers and is associated with negative outcomes. We aimed to evaluate if immunonutrition during neoadjuvant treatment improves patient's health-related quality of life (HRQOL) and reduces postoperative morbidity and toxicities during neoadjuvant treatment.

Methods: A multicenter double-blind randomized controlled trial (RCT) was undertaken.

View Article and Find Full Text PDF

Introduction: The objective of this study was to assess the effectiveness of ivermectin and colchicine as treatment options for coronavirus disease 2019 (COVID-19).

Methodology: A three-arm randomized controlled clinical trial was conducted in the Triage Clinic of the family medicine department at Ain Shams University Hospitals on participants who had been diagnosed with moderate COVID-19. Patients aged < 18 years or > 65 years, with any co-morbidities, pregnant or lactating females, and those with mild or severe COVID-19 confirmed cases were excluded.

View Article and Find Full Text PDF

Introduction: Inflammation plays a role in coronavirus disease 2019 (COVID-19) pathophysiology and anti-inflammatory drugs may help reduce the disease severity. Levamisole is an anthelmintic drug with immunomodulatory and possible antiviral effects. This study aimed to evaluate the role of levamisole in the treatment of patients with COVID-19.

View Article and Find Full Text PDF

Background: Stroke has devastating consequences for survivors. Hypertension is the most important modifiable risk factor, and its management largely takes place in primary care. However, most stroke-based research does not occur in this setting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!